Skip to main content
Breaking News
Feature Story

Viral crossroads

BioCentury is providing in-depth analysis of the sudden impact of social media on difficult medical and ethical decisions surrounding compassionate access to experimental medicines. See the story from a multitude of angles in our continuing coverage.


Full Article

Today's Biotech & Pharma News

Compassionate Access

  • COVER STORY

    Contaminating cancer genomes

    Two European teams have pinpointed a DNA-protective enzyme as a chemically tractable target whose inhibition kills cancer cells by accelerating DNA damage. Both groups have identified small molecule inhibitors of the enzyme and are looking to partner with industry.

  • TRANSLATIONAL NOTES

    Translational tidbits

    AstraZeneca had a busy March, announcing five new public-private partnerships and launching its Open Innovation website to list additional partnership opportunities.

  • Expanding into new (bromo)domains

    The Neomed Institute has begun development of its first cancer therapeutic, a BRD4 inhibitor from Epigenetix that the not-for-profit organization thinks could have a selectivity advantage over competing molecules.

  • TARGETS & MECHANISMS

    Unfolding triple-negative breast cancer

    A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers -- overactivation of the transcription factor X-box binding protein 1. Blocking expression of the target decreases tumor formation and relapse in mice, but more druggable targets upstream of it might be better suited for further development.

  • THERAPEUTICS

    This Week in Therapeutics

    Inhibiting IL-17A or IL-23 to alleviate periodontitis; antagonizing KCNA3 to treat asthma; activating CD31 signaling to counter autoimmune and inflammatory conditions; and more...

  • TECHNIQUES

    This Week in Techniques

    Isoacyl dipeptides to increase insulin yield from chemical synthesis; binary nylon-3 copolymers containing cationic and hydrophobic subunits for antimicrobial activity; markers of distinct SHH-driven medulloblastomas; and more...

Subscribe Now
Free Trial

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.